Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.

Blair BG, Larson CA, Safaei R, Howell SB.

Clin Cancer Res. 2009 Jul 1;15(13):4312-21. doi: 10.1158/1078-0432.CCR-09-0311. Epub 2009 Jun 9.

2.

Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.

Blair BG, Larson CA, Adams PL, Abada PB, Safaei R, Howell SB.

Mol Pharmacol. 2010 Jun;77(6):912-21. doi: 10.1124/mol.109.062836. Epub 2010 Mar 1.

3.

Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.

Samimi G, Howell SB.

Cancer Chemother Pharmacol. 2006 Jun;57(6):781-8. Epub 2005 Sep 17.

PMID:
16170571
4.
5.

The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.

Larson CA, Blair BG, Safaei R, Howell SB.

Mol Pharmacol. 2009 Feb;75(2):324-30. doi: 10.1124/mol.108.052381. Epub 2008 Nov 7.

6.

Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.

Huang CP, Fofana M, Chan J, Chang CJ, Howell SB.

Metallomics. 2014 Mar;6(3):654-61. doi: 10.1039/c3mt00331k. Epub 2014 Feb 13.

7.

Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.

Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB.

Clin Cancer Res. 2004 Jul 15;10(14):4661-9.

8.

Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.

Shang X, Lin X, Manorek G, Howell SB.

Mol Pharmacol. 2013 Jan;83(1):85-94. doi: 10.1124/mol.112.079798. Epub 2012 Oct 10.

9.

The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.

Lin X, Okuda T, Holzer A, Howell SB.

Mol Pharmacol. 2002 Nov;62(5):1154-9. Erratum in: Mol Pharmacol. 2003 Apr;63(4):957.

10.

Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.

Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB.

Cancer Res. 2002 Nov 15;62(22):6559-65.

11.

The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.

Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB.

Mol Pharmacol. 2003 Aug;64(2):466-73.

12.

Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.

Howell SB, Safaei R, Larson CA, Sailor MJ.

Mol Pharmacol. 2010 Jun;77(6):887-94. doi: 10.1124/mol.109.063172. Epub 2010 Feb 16. Review.

13.

Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.

Safaei R, Maktabi MH, Blair BG, Larson CA, Howell SB.

J Inorg Biochem. 2009 Mar;103(3):333-41. doi: 10.1016/j.jinorgbio.2008.11.012. Epub 2008 Nov 30.

14.

Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.

Safaei R, Howell SB.

Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23. Review.

PMID:
15607932
15.

Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.

Kalayda GV, Wagner CH, Jaehde U.

J Inorg Biochem. 2012 Nov;116:1-10. doi: 10.1016/j.jinorgbio.2012.07.010. Epub 2012 Jul 26.

PMID:
23010323
16.

Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.

Blair BG, Larson CA, Adams PL, Abada PB, Pesce CE, Safaei R, Howell SB.

Mol Pharmacol. 2011 Jan;79(1):157-66. doi: 10.1124/mol.110.068411. Epub 2010 Oct 7. Erratum in: Mol Pharmacol. 2011 May;79(5):894-8.

17.

Role of copper transporters in the uptake and efflux of platinum containing drugs.

Safaei R.

Cancer Lett. 2006 Mar 8;234(1):34-9. Epub 2005 Nov 16. Review.

PMID:
16297532
18.

Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.

Holzer AK, Katano K, Klomp LW, Howell SB.

Clin Cancer Res. 2004 Oct 1;10(19):6744-9.

19.

Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.

Yoshida H, Teramae M, Yamauchi M, Fukuda T, Yasui T, Sumi T, Honda K, Ishiko O.

Anticancer Res. 2013 Apr;33(4):1409-14.

PMID:
23564780
20.

Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.

Abada PB, Larson CA, Manorek G, Adams P, Howell SB.

Mol Pharmacol. 2012 Sep;82(3):510-20. doi: 10.1124/mol.112.079822. Epub 2012 Jun 18.

Items per page

Supplemental Content

Write to the Help Desk